Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1Unknown 1Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Post-transplant Lymphoproliferative Disease 1Plasmacytoma 1Lymphoma, Non-Hodgkin 1Leukemia 1Hodgkin Disease 1

Interventions

Cytarabine 35Cyclophosphamide 26Etoposide 18Radiotherapy 16Daunorubicin 16Busulfan 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Idarubicin 14Mercaptopurine 12Dexamethasone 12Vincristine 11Thioguanine 9Mitoxantrone 9Doxorubicin 8Asparaginase 8Antilymphocyte Serum 8pegaspargase 7fludarabine phosphate 7Prednisolone 7Polymerase Chain Reaction 7Filgrastim 7Cyclosporine 7Prednisone 6Mycophenolic Acid 5Melphalan 5Leucovorin 5Gene Expression Profiling 5Vindesine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia × Leukapheresis × Clear all
NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡